JP2018520093A - 注射可能なデポー製剤 - Google Patents

注射可能なデポー製剤 Download PDF

Info

Publication number
JP2018520093A
JP2018520093A JP2017558027A JP2017558027A JP2018520093A JP 2018520093 A JP2018520093 A JP 2018520093A JP 2017558027 A JP2017558027 A JP 2017558027A JP 2017558027 A JP2017558027 A JP 2017558027A JP 2018520093 A JP2018520093 A JP 2018520093A
Authority
JP
Japan
Prior art keywords
kinase inhibitor
subject
syringe
composition
injectable composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017558027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520093A5 (enExample
Inventor
アシュトン，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of JP2018520093A publication Critical patent/JP2018520093A/ja
Publication of JP2018520093A5 publication Critical patent/JP2018520093A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017558027A 2015-05-05 2016-05-05 注射可能なデポー製剤 Pending JP2018520093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
US62/157,257 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (2)

Publication Number Publication Date
JP2018520093A true JP2018520093A (ja) 2018-07-26
JP2018520093A5 JP2018520093A5 (enExample) 2019-06-13

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558027A Pending JP2018520093A (ja) 2015-05-05 2016-05-05 注射可能なデポー製剤

Country Status (10)

Country Link
US (1) US20160324836A1 (enExample)
EP (1) EP3291812B1 (enExample)
JP (1) JP2018520093A (enExample)
CN (1) CN107530334A (enExample)
AU (1) AU2016258001B2 (enExample)
BR (1) BR112017023762A2 (enExample)
CA (1) CA2984637A1 (enExample)
MX (1) MX385405B (enExample)
RU (1) RU2017137763A (enExample)
WO (1) WO2016179357A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541874A (ja) * 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
WO2013000909A1 (en) * 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CN104204804B (zh) * 2011-11-11 2016-09-28 因特利凯有限责任公司 激酶抑制剂的组合及其用途
AR089248A1 (es) * 2011-12-14 2014-08-06 Abbvie Inc Composiciones que contienen inhibidores de quinasas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, 2013, VOL.8, ISSUE 6, E65726,PP.1-13, JPN6020015456, ISSN: 0004261149 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541874A (ja) * 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物

Also Published As

Publication number Publication date
AU2016258001B2 (en) 2020-06-04
WO2016179357A1 (en) 2016-11-10
EP3291812A4 (en) 2019-01-09
MX2017014084A (es) 2018-06-20
MX385405B (es) 2025-03-18
CA2984637A1 (en) 2016-11-10
US20160324836A1 (en) 2016-11-10
EP3291812B1 (en) 2021-09-01
CN107530334A (zh) 2018-01-02
BR112017023762A2 (pt) 2018-07-31
RU2017137763A (ru) 2019-06-05
EP3291812A1 (en) 2018-03-14
AU2016258001A1 (en) 2017-11-09
RU2017137763A3 (enExample) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
EP3291812B1 (en) Injectable depot formulations
CN102695511A (zh) 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
KR101877041B1 (ko) 혈관 과투과성과 부종 및 이로부터 발생하는 다른 부작용을 저해하는 방법
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2007520496A (ja) 徐放性ステロイド組成物
BR112018014467A2 (en) drug-antibody synergism technology for disease treatment
TW201639569A (zh) 徐放性醫藥組成物
US20200030263A1 (en) Methods and compositions for promoting wound healing with decreased scar formation after glaucoma filtration surgery
EP2671589A1 (en) Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
KR20150105355A (ko) 질병을 치료하기 위한 방법
KR20030084926A (ko) 눈의 퇴행성신경질환의 치료를 위한가바-수용체-모듈레이터
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
US20110200662A1 (en) Method For The Treatment Of Proliferative Disorders Of The Eye
KR20230018418A (ko) 비정상적인 혈관형성을 치료하기 위한 국소 안과학적 조성물 및 방법
EP3305300B1 (en) Intravitreal lysine acetylsalicylate for use in the treatment of diabetic retinopathy
AU2024280284A1 (en) Complement antibody-drug conjugates
HK40111552A (zh) 用於治疗干眼综合征的包含瑞可黄酮的滴眼剂组合物及其制备方法
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией
JP2003342166A (ja) 眼内疾患用製剤
Zacharias et al. Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).
HK1228282A1 (en) Injectable agent and depot formation method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210126